Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

Comirnaty targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the XBB.1.5 subvariant ...

BioNTech's updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus. The ...

These five top stocks trade at reasonable levels and offer the strength that makes sense as we enter a very volatile time of ...

The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada ...

It’s been over four years since the beginning of the COVID-19 pandemic. And since then, the virus has changed substantially.

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...

Novavax's traditional protein-based shot offers an alternative vaccine technology to those that are based on messenger RNA - Moderna's Spikevax and Comirnaty, which is jointly developed by Pfizer ...